These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1380992)

  • 1. Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma.
    Stege R; Tribukait B; Lundh B; Carlström K; Pousette A; Hasenson M
    J Urol; 1992 Sep; 148(3):833-7. PubMed ID: 1380992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
    Stege R; Grande M; Carlström K; Tribukait B; Pousette A
    Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma.
    Stege R; Lundh B; Tribukait B; Pousette A; Carlström K; Hasenson M
    J Urol; 1990 Aug; 144(2 Pt 1):299-302. PubMed ID: 1695689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA ploidy and prostate-specific antigen as prognostic factors in clinically resectable prostate cancer.
    Badalament RA; O'Toole RV; Young DC; Drago JR
    Cancer; 1991 Jun; 67(12):3014-23. PubMed ID: 1710533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue PSA from fine-needle biopsies of prostatic carcinoma as related to serum PSA, clinical stage, cytological grade, and DNA ploidy.
    Stege RH; Tribukait B; Carlström KA; Grande M; Pousette AH
    Prostate; 1999 Feb; 38(3):183-8. PubMed ID: 10068342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases.
    Sebo TJ; Cheville JC; Riehle DL; Lohse CM; Pankratz VS; Myers RP; Blute ML; Zincke H
    Cancer; 2001 Jun; 91(11):2196-204. PubMed ID: 11391602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
    Nativ O; Myers RP; Farrow GM; Therneau TM; Zincke H; Lieber MM
    J Urol; 1990 Aug; 144(2 Pt 1):303-6. PubMed ID: 1695690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status.
    Ross JS; Nazeer T; Figge HL; Fisher HA; Rifkin MD
    Am J Clin Pathol; 1995 Jul; 104(1):36-41. PubMed ID: 7541934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer.
    Ross JS; Figge H; Bui HX; del Rosario AD; Jennings TA; Rifkin MD; Fisher HA
    Cancer; 1994 Nov; 74(10):2811-8. PubMed ID: 7954242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone sensitivity and to cytological grading.
    Hasenson M; Lundh B; Stege R; Carlström K; Pousette A
    Prostate; 1989; 14(2):83-90. PubMed ID: 2469074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
    Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
    Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology.
    Konchuba AM; Schellhammer PF; Kolm P; Clements MA; Wright GL
    J Urol; 1993 Jul; 150(1):115-9. PubMed ID: 7685419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients.
    Grande M; Carlström K; Rozell BL; Stege R; Pousette A
    Clin Cancer Res; 2000 May; 6(5):1790-5. PubMed ID: 10815899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer.
    Adolfsson J; Rönström L; Hedlund PO; Löwhagen T; Carstensen J; Tribukait B
    J Urol; 1990 Dec; 144(6):1404-6; discussion 1406-7. PubMed ID: 2231935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: modal deoxyribonucleic acid value and cytological differentiation.
    Adolfsson J; Tribukait B
    J Urol; 1990 Dec; 144(6):1408-10. PubMed ID: 2231936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
    Dundas GS; Porter AT; Venner PM
    Cancer; 1990 Jul; 66(1):45-8. PubMed ID: 1693877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
    Cooper EH; Armitage TG; Robinson MR; Newling DW; Richards BR; Smith PH; Denis L; Sylvester R
    Cancer; 1990 Sep; 66(5 Suppl):1025-8. PubMed ID: 1697498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate.
    Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA
    Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue PSA is the best predicting variable for the outcome of endocrine treatment of prostatic carcinoma.
    Pousette A; Grande M; Carlström K; Stege R
    Scand J Clin Lab Invest Suppl; 1999; 229():27-32. PubMed ID: 10097287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.